Viral vector vaccines.

COVID-19 / prevention & control Genetic Vectors / genetics Humans Pandemics / prevention & control SARS-CoV-2 Viral Vaccines

Journal

Current opinion in immunology
ISSN: 1879-0372
Titre abrégé: Curr Opin Immunol
Pays: England
ID NLM: 8900118

Informations de publication

Date de publication:
08 2022
Historique:
received: 13 03 2022
revised: 13 04 2022
accepted: 15 04 2022
pubmed: 2 6 2022
medline: 3 8 2022
entrez: 1 6 2022
Statut: ppublish

Résumé

Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future.

Identifiants

DOI: 10.1016/j.coi.2022.102210 PMID: 35643023 PMC: PMC9612401
pubmed: 35643023
pii: S0952-7915(22)00057-7
doi: 10.1016/j.coi.2022.102210
pmc: PMC9612401
pii:
doi:

Substances chimiques

Viral Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102210

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Références

Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
JAMA. 2017 Mar 14;317(10):1075-1077
pubmed: 28291882
J Infect Dis. 2019 Aug 30;220(7):1127-1135
pubmed: 31505665
J Virol. 2007 Feb;81(3):1305-12
pubmed: 17108047
J Infect Dis. 2003 Oct 15;188(8):1213-30
pubmed: 14551893
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
J Virol. 2004 Oct;78(20):11434-8
pubmed: 15452269
J Infect Dis. 2018 Nov 5;218(12):1883-1889
pubmed: 29982595
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Hum Vaccin Immunother. 2017 Sep 2;13(9):2078-2085
pubmed: 28708962
Lancet Infect Dis. 2020 Jul;20(7):816-826
pubmed: 32325038
N Engl J Med. 2021 Sep 2;385(10):951-953
pubmed: 34260834
Expert Rev Vaccines. 2019 Aug;18(8):765-779
pubmed: 31271322
Clin Vaccine Immunol. 2008 Apr;15(4):691-6
pubmed: 18272665
Lancet. 2014 Oct 11;384(9951):1358-65
pubmed: 25018116
Science. 2021 Jan 29;371(6528):521-526
pubmed: 33510029
Vaccines (Basel). 2021 Aug 27;9(9):
pubmed: 34579196
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
J Immunol. 2004 May 15;172(10):6290-7
pubmed: 15128818
Lancet Glob Health. 2017 Mar;5(3):e324-e334
pubmed: 28017642
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell Mol Immunol. 2022 Mar;19(3):447-448
pubmed: 35043006
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
Lancet Infect Dis. 2020 Apr;20(4):455-466
pubmed: 31952923
Expert Rev Vaccines. 2020 Jan;19(1):25-41
pubmed: 31889453
Hum Vaccin. 2010 Dec;6(12):1038-46
pubmed: 21150279
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
N Engl J Med. 2015 Jan 8;372(2):113-23
pubmed: 25365753
Vaccine. 2016 Jan 20;34(4):413-423
pubmed: 26691569
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Sci Rep. 2020 Mar 31;10(1):5716
pubmed: 32235848
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Nat Commun. 2021 Nov 26;12(1):6871
pubmed: 34836955
BMC Genomics. 2021 Oct 30;22(1):777
pubmed: 34717548
J Virol. 2011 Jan;85(1):315-23
pubmed: 20962088
Mol Ther. 2007 Feb;15(2):393-403
pubmed: 17235319
Lancet Infect Dis. 2022 Jan;22(1):97-109
pubmed: 34529963
Nat Commun. 2013;4:2836
pubmed: 24284865
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Nat Med. 2014 Oct;20(10):1126-9
pubmed: 25194571
Front Immunol. 2020 May 19;11:909
pubmed: 32508823
PLoS Pathog. 2021 Nov 29;17(11):e1010016
pubmed: 34843602
Lancet. 2022 Jan 1;399(10319):36-49
pubmed: 34883053
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
Vaccine. 2011 Jul 18;29(32):5203-9
pubmed: 21619905
Hum Vaccin Immunother. 2017 Mar 4;13(3):613-620
pubmed: 28152326
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Lancet. 2020 Aug 15;396(10249):479-488
pubmed: 32702299
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
J Virol. 2015 Jan;89(1):669-75
pubmed: 25355873
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
J Clin Invest. 2015 Mar 2;125(3):1129-46
pubmed: 25642773
J Infect Dis. 2019 Apr 8;219(8):1187-1197
pubmed: 30407513
Immun Ageing. 2021 Aug 20;18(1):34
pubmed: 34416887
Lancet. 2022 Jan 15;399(10321):237-248
pubmed: 34953526
Nature. 1984 Sep 6-11;311(5981):67-9
pubmed: 6472464
Front Immunol. 2021 May 20;12:685218
pubmed: 34093588
Vaccines (Basel). 2020 Feb 02;8(1):
pubmed: 32024265
Lancet Infect Dis. 2016 Jan;16(1):31-42
pubmed: 26546548
PLoS One. 2018 Feb 20;13(2):e0192312
pubmed: 29462200
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Lancet Infect Dis. 2021 Apr;21(4):493-506
pubmed: 33217361
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
J Infect Dis. 2013 Jan 15;207(2):240-7
pubmed: 23125444
Lancet Reg Health Eur. 2021 Dec;11:100241
pubmed: 34746910
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
J Immunol. 2008 Aug 1;181(3):2134-44
pubmed: 18641352
Vaccine. 2010 Nov 23;28(50):7993-8000
pubmed: 20934459
Sci Adv. 2021 Dec 03;7(49):eabl8213
pubmed: 34851659
J Infect Dis. 2019 Jun 5;220(1):57-67
pubmed: 30796816
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Front Immunol. 2020 Nov 30;11:579872
pubmed: 33329551
Lancet Infect Dis. 2021 Dec;21(12):1654-1664
pubmed: 34324836
J Infect Dis. 2021 Mar 29;223(6):1062-1072
pubmed: 32726422
J Virol. 2018 Aug 16;92(17):
pubmed: 29925653
Lancet. 2017 Feb 11;389(10069):621-628
pubmed: 28017399
Nat Immunol. 2018 Nov;19(11):1169-1178
pubmed: 30333617
Lancet Glob Health. 2022 Jan;10(1):e33-e34
pubmed: 34919849
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Nature. 1983 Apr 7;302(5908):490-5
pubmed: 6835382
Nat Commun. 2021 May 17;12(1):2893
pubmed: 34001897

Auteurs

Naina McCann (N)

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: Naina.mccann@paediatrics.ox.ac.uk.

Daniel O'Connor (D)

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Teresa Lambe (T)

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Viral vector vaccines.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Vecteurs génétiques › Viral vector vaccines.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Viral vector vaccines.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Viral vector vaccines.
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Viral vector vaccines.
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Viral vector vaccines.